文献速递造血干细胞移植与细胞治疗

伊他替尼单药有效治疗低危急性移植物抗宿主病

Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
PubMed 文献 · Blood · 2023-01-01

在多中心2期试验中,70例低危急性GVHD患者接受伊他替尼200 mg/d治疗28天,并与140例同期匹配的接受全身性糖皮质激素治疗的患者比较。伊他替尼组7天内应答率更高(81% vs 66%,P=0.02),90天内严重感染更少(27% vs 42%,P=0.04),两组28天应答率、1年非复发死亡率、复发、慢性GVHD和生存均无显著差异。

要点

  • 伊他替尼单药治疗低危急性GVHD,7天内应答率81% vs 66%(P=0.02)。
  • 90天内严重感染发生率伊他替尼组27% vs 42%(P=0.04),病毒和真菌感染更少。
  • 1年非复发死亡率、复发、慢性GVHD和生存两组无显著差异。

核心结论

  • 伊他替尼单药似乎是低危急性GVHD安全有效的替代全身性糖皮质激素的治疗,值得进一步研究。

研究设计与样本

  • 多中心2期试验(NCT03846479),70例低危急性GVHD患者接受伊他替尼200 mg/d治疗28天,应答者可再接受第二个28天周期。
  • 与140例同期匹配的接受全身性糖皮质激素治疗的对照患者比较结局。

主要发现

  • 伊他替尼组7天内应答率81% vs 对照组66%(P=0.02)。
  • 第28天应答率两组分别为89% vs 86%(P=0.67),症状 flare 分别为11% vs 12%(P=0.88)。
  • 90天内严重感染发生率伊他替尼组27% vs 对照组42%(P=0.04),因病毒和真菌感染更少。
  • ≥3级血细胞减少两组相似,但伊他替尼组白细胞减少更轻(16% vs 31%,P=0.02)。
  • 1年非复发死亡率4% vs 11%(P=0.21)、复发18% vs 21%(P=0.64)、慢性GVHD 28% vs 33%(P=0.33)、生存88% vs 80%(P=0.11),均无显著差异。

关键数值与推荐

  • 使用经过验证的临床和生物标志物分期标准识别低危急性GVHD患者。
  • 伊他替尼剂量为200 mg/d,治疗28天,应答者可再接受第二个28天周期。

临床怎么用

  • 作者认为伊他替尼单药似乎是低危急性GVHD安全有效的替代全身性糖皮质激素的治疗,值得进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The standard primary treatment for acute graft-versus-host disease (GVHD) requires prolonged, high-dose systemic corticosteroids (SCSs) that delay reconstitution of the immune system. We used validated clinical and biomarker staging criteria to identify a group of patients with low-risk (LR) GVHD that is very likely to respond to SCS. We hypothesized that itacitinib, a selective JAK1 inhibitor, would effectively treat LR GVHD without SCS. We treated 70 patients with LR GVHD in a multicenter, phase 2 trial (NCT03846479) with 28 days of itacitinib 200 mg/d (responders could receive a second 28-day cycle), and we compared their outcomes to those of 140 contemporaneous, matched control patients treated with SCSs. More patients responded to itacitinib within 7 days (81% vs 66%, P = .02), and response rates at day 28 were very high for both groups (89% vs 86%, P = .67), with few symptomatic flares (11% vs 12%, P = .88). Fewer itacitinib-treated patients developed a serious infection within 90 days (27% vs 42%, P = .04) due to fewer viral and fungal infections. Grade ≥3 cytopenias were similar between groups except for less severe leukopenia with itacitinib (16% vs 31%, P = .02). No other grade ≥3 adverse events occurred in >10% of itacitinib-treated patients. There were no significant differences between groups at 1 year for nonrelapse mortality (4% vs 11%, P = .21), relapse (18% vs 21%, P = .64), chronic GVHD (28% vs 33%, P = .33), or survival (88% vs 80%, P = .11). Itacitinib monotherapy seems to be a safe and effective alternative to SCS treatment for LR GVHD and deserves further investigation.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Etra A, Capellini A, Alousi A, et al. Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Blood. 2023. PMID: 36095841. doi:10.1182/blood.2022017442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。